NuCana (NCNA) Stock: Buy, Sell, or Hold?
NCNA - NuCana plc American Depositary Share
$1.32
-0.02 (-1.49%)
▼
5d:
-7.69%
30d:
-7.69%
90d:
-33.67%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 19, 2026
0d
Get Alerted When NCNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NCNA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NCNA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NCNA is currently trading at $1.32, which is considered oversold relative to its 30-day fair value range of $1.37 to $1.55.
Technical Outlook: Technically, NCNA is in a strong downtrend. The price is currently testing key support at $1.32. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NCNA scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $104.00 (+7778.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NCNA is in a strong downtrend. The price is currently testing key support at $1.32. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NCNA scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $104.00 (+7778.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.37 -
$1.55
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 7778.8% below Wall St target ($104.00)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.37 -
$1.55
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.32
Resistance Level
$1.90
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-25.38
Wall Street Target
$104.00
(+7778.8%)
Share & Embed Analysis
Last updated: September 13, 2026 6:54 PM ET
Data refreshes hourly during market hours. Next update: 7:54 PM
Data refreshes hourly during market hours. Next update: 7:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NCNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
